Shangwen Jiang

Shangwen Jiang

Auto-generated profile, based on publicly available information

Shangwen Jiang

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Cell
Verified
Journal Article
Closed access
JXJun-Yu Xu
Jun-Yu Xu
CZChunchao Zhang
Chunchao Zhang
XWXiang Wang
Xiang Wang
LZLinhui Zhai
Linhui Zhai
YMYiming Ma
Yiming Ma
MTMinjia Tan
Minjia Tan

13 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
BLBin Liu
Bin Liu
SJShangwen Jiang
Shangwen Jiang
MLMin Li
Min Li
XXXuelian Xiong
Xuelian Xiong
MZMingrui Zhu
Mingrui Zhu
MTMinjia Tan
Minjia Tan
Ubiquitin-specific protease 14 (USP14) is one of the major proteasome-associated deubiquitinating enzymes critical for proteome homeostasis. However, substrates of USP14 remain largely unknown, hindering the understanding of its functional roles. Here we conduct a comprehensive proteome, ubiquitinome and interactome analysis for USP14 substrate screening. Bioinformatics analysis reveals broad new potential roles of USP14, especially in lipid and carbohydrate metabolism. Among the potential substrates identified, we show that fatty acid synthase (FASN), a key enzyme involved in hepatic lipogenesis, is a bona fide substrate of USP14. USP14 directly interacts with and increases FASN stability. As a result, overexpression of USP14 promotes liver triglyceride accumulation in C57BL/6 mice, whereas genetic ablation or pharmacological inhibition of USP14 ameliorates hepatosteatosis, hyperglycemia and insulin resistance in obese mice. In conclusion, our findings reveal for the first time an indispensable role of USP14 in hepatosteatosis through FASN stabilization.

1 July 2017 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
LNLitong Nie
Litong Nie
LSLin Shuai
Lin Shuai
MZMingrui Zhu
Mingrui Zhu
PLPing Liu
Ping Liu
ZXZhi-Fu Xie
Zhi-Fu Xie
MTMinjia Tan
Minjia Tan
Type 2 diabetes (T2D) is a major chronic healthcare concern worldwide. Emerging evidence suggests that a histone-modification-mediated epigenetic mechanism underlies T2D. Nevertheless, the dynamics of histone marks in T2D have not yet been carefully analyzed. Using a mass spectrometry-based label-free and chemical stable isotope labeling quantitative proteomic approach, we systematically profiled liver histone post-translational modifications (PTMs) in a prediabetic high-fat diet-induced obese (DIO) mouse model. We identified 170 histone marks, 30 of which were previously unknown. Interestingly, about 30% of the histone marks identified in DIO mouse liver belonged to a set of recently reported lysine acylation modifications, including propionylation, butyrylation, malonylation, and succinylation, suggesting possible roles of these newly identified histone acylations in diabetes and obesity. These histone marks were detected without prior affinity enrichment with an antibody, demonstrating that the histone acylation marks are present at reasonably high stoichiometry. Fifteen histone marks differed in abundance in DIO mouse liver compared with liver from chow-fed mice in label-free quantification, and six histone marks in stable isotope labeling quantification. Analysis of hepatic histone modifications from metformin-treated DIO mice revealed that metformin, a drug widely used for T2D, could reverse DIO-stimulated histone H3K36me2 in prediabetes, suggesting that this mark is likely associated with T2D development. Our study thus offers a comprehensive landscape of histone marks in a prediabetic mouse model, provides a resource for studying epigenetic functions of histone modifications in obesity and T2D, and suggest a new epigenetic mechanism for the physiological function of metformin.

1 October 2021 in Molecular Cell
Verified
Journal Article
Closed access
ZLZhiwei Liu
Zhiwei Liu
YLYingluo Liu
Yingluo Liu
LQLili Qian
Lili Qian
SJShangwen Jiang
Shangwen Jiang
XGXiameng Gai
Xiameng Gai
MTMinjia Tan
Minjia Tan

15 May 2017 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
PLPhilbert Lee
Philbert Lee
SJShangwen Jiang
Shangwen Jiang
YLYuanyuan Li
Yuanyuan Li
JYJiping Yue
Jiping Yue
XGXuewen Gou
Xuewen Gou
XWXiaoyang Wu
Xiaoyang Wu

17 February 2021 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
YJYuejing Jiang
Yuejing Jiang
XCXiaoji Cong
Xiaoji Cong
SJShangwen Jiang
Shangwen Jiang
YDYing Dong
Ying Dong
LZLei Zhao
Lei Zhao
JLJia Li
Jia Li
AMP-activated protein kinase (AMPK) is a conserved energy sensor that plays roles in diverse biological processes via phosphorylating various substrates. Emerging studies have demonstrated the regulatory roles of AMPK in DNA repair, but the underlying mechanisms remain to be fully understood. Herein, using mass spectrometry-based proteomic technologies, we systematically investigate the regulatory network of AMPK in DNA damage response (DDR). Our system-wide phosphoproteome study uncovers a variety of newly-identified potential substrates involved in diverse biological processes, whereas our system-wide histone modification analysis reveals a link between AMPK and histone acetylation. Together with these findings, we discover that AMPK promotes apoptosis by phosphorylating apoptosis-stimulating of p53 protein 2 (ASPP2) in an irradiation (IR)-dependent manner and regulates histone acetylation by phosphorylating histone deacetylase 9 (HDAC9) in an IR-independent manner. Besides, we reveal that disrupting the histone acetylation by the bromodomain BRD4 inhibitor JQ-1 enhances the sensitivity of AMPK-deficient cells to IR. Therefore, our study has provided a resource to investigate the interplay between phosphorylation and histone acetylation underlying the regulatory network of AMPK, which could be beneficial to understand the exact role of AMPK in DDR.